PROGNOSTIC VALUE OF EXPRESSION OF ANDROGENETIC RECEPTORS IN DIFFERENT MOLECULAR TYPES OF BREAST CANCER
https://doi.org/10.17650/1726-9784-2017-16-1-32-37
Abstract
Introduction. So far in the literature there is no consensus on the relationship between the level of androgens and their metabolites in various biological fluids and tissues with the development of breast cancer. As suggested by many researchers, determining the level of androgenetic receptors (AR) in the tumor in patients with breast cancer are able to access a number of promising directions in the study of prognosis of the disease and the search for new approaches to endocrine therapy of different molecular subtypes of breast cancer. Objective. To evaluate the clinical and prognostic significance of the immunohistochemical expression of AR in different molecular types of breast cancer. Materials and methods. In the present work we have studied the expression of AR in tumor tissue in patients of different molecular types of breast cancer. Results. The risk of death in patients with AR-positive breast cancer is 88 % lower than in patients with AR-negative tumors. Conclusion. It was concluded that the study of the expression of AR, is a promising direction not only in the assessment of the prognosis of the disease, but when searching for additional approaches to the treatment of breast cancer.
About the Authors
D. A. Ryabchikov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
I. K. Vorotnikov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
N. A. Kozlov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
N. V. Chkhikvadze
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
K. S. Titov
Moscow Clinical Research Center
Russian Federation
Russian Federation
A. S. Shusharin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. С. 5-11.
2. Safarpour D., Tavassoli F.A. A Targetable Androgen Receptor - Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. Arch Pathol Lab Med 2015; 139(5): 612-7. DOI: 10.5858/arpa.2014-0122-RA. PMID: 25310144.
3. Крылов А.Ю., Крылов Ю.В. Андрогены и рак молочной железы (обзор литературы). Вестник Витебского гос. мед. ин-та 2015; 5(14): 5-15.
4. Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit 2000; 6(2): 433-8. PMID: 11208351.
5. Liao D.J., Dickson R.B. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002; 80(2): 175-89. PMID: 11897502.
6. Isola J.J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993; 170(1): 31-5. DOI: 10.1002/path.1711700106. PMID: 8100853.
7. Hu R., Dawood S., Holmes M.D. et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011; 17(7): 1867-74. DOI: 10.1158/1078-0432.CCR-10-2021. PMID: 21325075. PMCID: PMC3076683.
8. Moinfar F., Okcu M., Tsybrovskyy O. et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003; 98(4): 703-11. DOI: 10.1002/cncr.11532. PMID: 12910513.
9. Ogawa Y., Hai E., Matsumoto K. et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008; 13(5): 431-5. DOI: 10.1007/s10147-008-0770-6. PMID: 18946753.
10. Lester S.C., Bose S., Chen Y.Y. et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 2009; 133(10): 1515-38. DOI: 10.1043/1543-2165-133.10.1515. PMID: 19792042.
11. Tang D., Xu S., Zhang Q., Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Medical Oncol 2012; 29(2): 526-33. DOI: 10.1007/s12032-011-9948-2. PMID: 21519872.
12. Federici C., Petrucci F., Caimi S. et al. Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE 2014; 9(2): e88193. DOI: 10.1371/journal.pone.0088193. PMID: 24516610. PMCID: PMC3916404.
13. Panet-Raymond V., Gottlieb B., Beitel L. K. et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000; 167(1-2): 139-50. PMID: 11000528.
14. Tokunaga E., Hisamatsu Y., Taketani K. et al. Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Med 2013; 2(6): 763-73. DOI: 10.1002/cam4.138. PMID: 24403250. PMCID: PMC3892381.
15. McGhan L. J., McCullough A.E., Protheroe C.A. et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2014; 21(2): 361-67. DOI: 10.1245/s10434-013-3260-7. PMID: 24046116.
16. Mrklic I., Pogorelic Z., Capkun V., Tomic S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochemica 2013; 115(4): 344-48. DOI: 10.1016/j.acthis.2012.09.006. PMID: 23031358.
Review
For citations:
Ryabchikov D.A., Vorotnikov I.K., Kozlov N.A., Chkhikvadze N.V., Titov K.S., Shusharin A.S. PROGNOSTIC VALUE OF EXPRESSION OF ANDROGENETIC RECEPTORS IN DIFFERENT MOLECULAR TYPES OF BREAST CANCER. Russian Journal of Biotherapy. 2017;16(1):32-37. (In Russ.) https://doi.org/10.17650/1726-9784-2017-16-1-32-37
Views:
475
Email this article 
